Atomoxetine hydrochloride + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Aug 1, 2007 → Feb 1, 2009

NCT ID

NCT00510276

About Atomoxetine hydrochloride + Placebo

Atomoxetine hydrochloride + Placebo is a approved stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00510276. Target conditions include Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (20) Terminated (3) Active (0)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine + PlaceboEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00700427	Phase 3	Completed	Jun 1, 2008	Oct 1, 2013	Attention Deficit Hyperactivity Disorder
NCT00510276	Approved	Completed	Aug 1, 2007	Feb 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00190879	Approved	Completed	Jun 1, 2005	May 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00191945	Phase 3	Completed	May 1, 2005	Feb 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00191906	Approved	Completed	Apr 1, 2005	Dec 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00190775	Approved	Completed	Sep 1, 2004	Oct 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00190736	Approved	Completed	Sep 1, 2004	Sep 1, 2006	ADHD
NCT00485459	Phase 3	Completed	Feb 1, 2004	Nov 1, 2004	Attention Deficit Hyperactivity Disorder
NCT00191698	Phase 3	Completed	Dec 1, 2003	Nov 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00190931	Approved	Completed	Nov 1, 2003	Jul 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00191009	Phase 2/3	Completed	Oct 1, 2003	Jan 1, 2006	Alzheimer Disease
NCT00486122	Approved	Completed	Sep 1, 2003	Jun 1, 2004	Attention Deficit Hyperactivity Disorder

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
CLONICEL (Clonidine HCl sustained release)	Shionogi	Phase 3	40
Donepezil hydrochloride + Placebo	Eisai	Phase 3	40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)	Eli Lilly	Phase 2/3	38
Atomoxetine + Placebo	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo	Eli Lilly	Phase 3	40